Nathan A. Pennell, MD, PhD

Nathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the importance of developing new RET inhibitors for patients with non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the study design and goals of an ongoing phase 1 trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with&nbsp;<a>lung cancer.</a>&nbsp;He shares his advice on what to do for patients who need therapy immediately, as well.